1.6
Impact Factor
1.9
CiteScore
28 days
Submission to First Decision
5 days
Acceptance to Publication

Pharmacoepidemiology, Volume 1, Issue 3

2022 December - 2 articles

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (2)

Select all

Article

10 Citations

8,404 Views

12 Pages

Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States

Tianyu Sun,
Natallia Katenka,
Stephen Kogut,
Jeffrey Bratberg,
Josiah Rich and
Ashley Buchanan

Pharmacoepidemiology2022, 1(3), 101-112;https://doi.org/10.3390/pharma1030010

24 November 2022

Opioid use disorder (OUD) is a chronic disease requiring long-term treatment and is associated with opioid overdose and increased risk of mortality. However, existing randomized clinical trials focused on short-term treatment engagement and detoxific...

(This article belongs to the Special Issue Pharmacoepidemiology and Addiction)

Full Article

Brief Report

4 Citations

9,962 Views

12 Pages

Spironolactone Utilization among Patients with Reduced and Preserved Ejection Fraction Heart Failure

Efe Eworuke,
Austin Cosgrove,
Qoua Liang Her,
Jennifer G. Lyons,
Dave Martin and
Sruthi Adimadhyam

Pharmacoepidemiology2022, 1(3), 89-100;https://doi.org/10.3390/pharma1030009

20 October 2022

Background: Spironolactone is a mineralocorticoid receptor antagonist indicated for the management of heart failure with reduced ejection fraction (HFrEF). In a previous clinical trial, spironolactone significantly lowered the incidence of heart fail...

Full Article

Pharmacoepidemiology - ISSN 2813-0618

Imprint

Download Flyer